首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >A Network Pharmacology Approach to Evaluating the Efficacy of Chinese Medicine Using Genome-Wide Transcriptional Expression Data
【24h】

A Network Pharmacology Approach to Evaluating the Efficacy of Chinese Medicine Using Genome-Wide Transcriptional Expression Data

机译:使用网络基因组转录表达数据评估中药功效的网络药理学方法

获取原文
获取原文并翻译 | 示例
           

摘要

The research of multicomponent drugs, such as in Chinese Medicine, on both mechanism dissection and drug discovery is challenging, especially the approaches to systematically evaluating the efficacy at a molecular level. Here, we presented a network pharmacology-based approach to evaluating the efficacy of multicomponent drugs by genome-wide transcriptional expression data and applied it to Shenmai injection (SHENMAI), a widely used Chinese Medicine composed of red ginseng (RG) and Radix Ophiopogonis (RO) in clinically treating myocardial ischemia (MI) diseases. The disease network, MI network in this case, was constructed by combining the protein-protein interactions (PPI) involved in the MI enriched pathways. The therapeutic efficacy of SHENMAI, RG, and RO was therefore evaluated by a network parameter, namely, network recovery index (NRI), which quantitatively evaluates the overall recovery rate in MI network. The NRI of SHENMAI, RG, and RO were 0.876,0.494, and 0.269 respectively, which indicated SHENMAI exerts protective effects and the synergistic effect of RG and RO on treating myocardial ischemia disease. The successful application of SHENMAI implied that the proposed network pharmacology-based approach could help researchers to better evaluate a multicomponent drug on a systematic and molecular level.
机译:关于中药等多成分药物的机理分析和药物发现的研究具有挑战性,尤其是在分子水平上系统评价疗效的方法。在这里,我们介绍了一种基于网络药理学的方法,可通过全基因组转录表达数据评估多组分药物的疗效,并将其应用于神麦注射液(SHENMAI),这是一种由红参(RG)和麦冬(Radix Ophiopogonis)组成的中药, RO)在临床上治疗心肌缺血(MI)疾病。通过组合参与MI富集途径的蛋白质-蛋白质相互作用(PPI),构建了疾病网络(在本例中为MI网络)。因此,通过网络参数(即网络恢复指数(NRI))评估SHENMAI,RG和RO的疗效,该参数定量评估MI网络的总体恢复率。 SHENMAI,RG和RO的NRI分别为0.876、0.494和0.269,这表明SHENMAI对心肌缺血性疾病具有保护作用,而RG和RO的协同作用则更高。 SHENMAI的成功应用表明,基于网络药理学的拟议方法可以帮助研究人员在系统和分子水平上更好地评估多组分药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号